Showing 3581-3590 of 4164 results for "".
- Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-releases-expanded-results-from-allergen-chamber-trial-and-announces-plans-to-initiate-the-phase-3-invigorate-trial-in-patients-with-allergic-conjunctivitis/2477060/Aldeyra Therapeutics announced expanded results from the company’s allergen chamber clinical methods trial of topical ocular reproxalap in patients with allergic conjunctivitis, and phase 3 clinical trial plans based on recent feedback from the FDA. “The expanded results from our allergen
- Promedica International and Dr. Agarwal’s Eye Hospitals Form Strategic Alliancehttps://modernod.com/news/promedica-international-and-dr-agarwals-eye-hospitals-form-strategic-alliance-2/2476709/Promedica International (PMI) and Dr. Agarwal’s Eye Hospitals (AEH) have formed a new partnership to conduct clinical trials in India. PMI and AEH stated that the alliance will enable them to collaboratively enroll and manage clinical studies in an expanded patient population, while conforming wi
- Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meetinghttps://modernod.com/news/immunocore-to-present-new-tebentafusp-imcgp100-data-in-advanced-melanoma-at-upcoming-2019-asco-annual-meeting/2476605/Immunocore Limited, a T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3, 2019. Teben
- Asepticys Files 510k Submission With FDA for TriFlect Disinfection Technologyhttps://modernod.com/news/asepticys-files-510k-submission-with-fda-for-triflect-disinfection-technology/2476450/Asepticys announced the completion of multisite human clinical trials for Asepticys’ novel contact lens care solution containing TriFlect technology. The company has submitted a 510(k) application to the FDA. The clinical trials involved over 320 patients at 12 sites across
- Retreatment With A Single TearCare Treatment Continues To Provide Relief For Patients With Dry Eye Diseasehttps://modernod.com/news/retreatment-with-a-single-tearcare-treatment-continues-to-provide-relief-for-patients-with-dry-eye-disease/2476302/A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release. The
- Janssen Enters License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseaseshttps://modernod.com/news/janssen-enters-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases/2476340/The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leadin
- FDA to Boost Staff to Help Handle Anticipated Increase in Cell and Gene Therapy Filingshttps://modernod.com/news/fda-to-boost-staff-to-help-handle-anticipated-increase-in-cell-and-gene-therapy-filings/2476185/FDA Commissioner Scott Gottlieb said Tuesday that the agency’s “eventual goal” is to add about 50 additional clinical reviewers to the group that oversees the clinical investigation, development, and review of cell and gene therapy products. He also cited the more than 800 activ
- First Patient Successfully Implanted with Implandata’s Eye Pressure Sensor for Continual Glaucoma Monitoringhttps://modernod.com/news/first-patient-successfully-implanted-with-implandatas-eye-pressure-sensor-for-continual-glaucoma-monitoring/2476170/Ophthalmic medical device company Implandata Ophthalmic Products announced that the first patient in its international, multicenter, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the supr
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi
- Bio-Tissue Highlights Publication of DREAM Studyhttps://modernod.com/news/bio-tissue-highlights-publication-of-dream-study/2480079/Bio-Tissue highlighted the publication of the Dry Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.[1] This retrospective study was conducted at 10 clinical sites in the United States, led by Marguerite McDonald, MD, and Hosam Sheha, MD. It demonstrates that a single applica